Anixa is focused on harnessing the bodyâs immune system in the fight against cancer. Anixaâs therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixaâs diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the bodyâs immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Source
No articles found.
Maternova, Inc. is the trusted resource for cutting edge medical innovations in ne...
Maternova, Inc. is the trusted resource for cut...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solut...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully...
We are a leading innovator and manufacturer of X-ray imaging components, including...
We are a leading innovator and manufacturer of ...
Tactile Medical is a leader in developing and marketing at-home therapy devices th...
Tactile Medical is a leader in developing and m...
Join the National Investor Network and get the latest information with your interests in mind.